Lesions of area postrema and subfornical organ alter exendin-4-induced brain activation without preventing the hypophagic effect of the GLP-1 receptor agonist.
The mechanism and route whereby glucagon-like peptide 1 (GLP-1) receptor agonists, such as GLP-1 and exendin-4 (Ex-4), access the central nervous system (CNS) to exert their metabolic effects have yet to be clarified. The primary objective of the present study was to investigate the potential role of two circumventricular organs (CVOs), the area postrema (AP) and the subfornical organ (SFO), in mediating the metabolic and CNS-stimulating effects of Ex-4. We demonstrated that electrolytic ablation of the AP, SFO, or AP + SFO does not acutely prevent the anorectic effects of Ex-4. AP + SFO lesion chronically decreased food intake and body weight and also modulated the effect of Ex-4 on the neuronal activation of brain structures involved in the hypothalamic-pituitary-adrenal axis and glucose metabolism. The results of the study also showed that CVO lesions blunted Ex-4-induced expression of c-fos mRNA (a widely used neuronal activity marker) in 1) limbic structures (bed nucleus of the stria terminalis and central amygdala), 2) hypothalamus (paraventricular hypothalamic nucleus, supraoptic nucleus, and arcuate nucleus), and 3) hindbrain (lateral and lateral-external parabrachial nucleus, medial nucleus of the solitary tract, and ventrolateral medulla). In conclusion, although the present results do not support a role for the CVOs in the anorectic effect induced by a single injection of Ex-4, they suggest that the CVOs play important roles in mediating the actions of Ex-4 in the activation of CNS structures involved in homeostatic control.
Baraboi
Elena-Dana
ED
Institut Universitaire de Cardiologie et dePneumologie de Québec, Quebec, Canada.
Smith
Pauline
P
Ferguson
Alastair V
AV
Richard
Denis
D
D000818:Animals; D031608:Area Postrema / Q000503:physiopathology*; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000201:enzymology / Q000503:physiopathology; D003680:Deglutition Disorders / Q000139:chemically induced / Q000503:physiopathology; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D000077270:Exenatide; D016762:Genes, fos; D005941:Glucokinase / Q000235:genetics; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D008297:Male; D009929:Organ Size; D010455:Peptides / Q000494:pharmacology*; D012332:RNA, Heterogeneous Nuclear / Q000235:genetics; D012333:RNA, Messenger / Q000187:drug effects / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar; D013356:Subfornical Organ / Q000503:physiopathology*; D014688:Venoms / Q000494:pharmacology*
D007004:Hypoglycemic Agents; D010455:Peptides; D012332:RNA, Heterogeneous Nuclear; D012333:RNA, Messenger; D014688:Venoms; D000077270:Exenatide; D005941:Glucokinase